NCT04744532: iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study |
|
|
| Recruiting | 1/2 | 49 | Japan | Bosutinib (Phase 1 part), PF-05208763, Bosutinib (Phase 2 part) | Kyoto University, Tokushima University, Kitasato University, Tottori University, Nara Medical University, Toho University, Hiroshima University, Pfizer | Amyotrophic Lateral Sclerosis | 03/24 | 03/24 | | |